Floatz logo

FULVESTRANT

a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

UNICANCERSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status cohort.

Asset / SponsorPhaseRating
Atezolizumab
National Cancer Institute (NCI)
Phase 3B
Eloxatin
National Cancer Institute (NCI)
Phase 3B
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 3B
METHYLPREDNISOLONE ACETATE IMPURITY E
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2CCC
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2CCC

View all 15 →

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant
BB
Indicative ·
70 / 100
View asset →
hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →